Staff Members - Benha University
Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease Results From the Registry of Pregnancy and Cardiac Disease
• 2018
Publication Information
Authors
Iris M. van Hagen, MD,
PhD
Sara A. Thorne, MD
Nasser Taha, MD
Ghada Youssef, MD
Amro Elnagar, MD
Harald Gabriel, MD
Yahia ElRakshy, MD
Bernard Iung, MD
Mark R. Johnson, MD,
PhD
Roger Hall, MD
Jolien W. Roos-Hesselink,
MD,
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
BACKGROUND: Cardiac disease is 1 of the major causes of maternal
mortality. We studied pregnancy outcomes in women with rheumatic
mitral valve disease.
METHODS: The Registry of Pregnancy and Cardiac Disease is an
international prospective registry, and consecutive pregnant women with
cardiac disease were included. Pregnancy outcomes in all women with
rheumatic mitral valve disease and no prepregnancy valve replacement
is described in the present study (n=390). A maternal cardiac event was
defined as cardiac death, arrhythmia requiring treatment, heart failure,
thromboembolic event, aortic dissection, endocarditis, acute coronary
syndrome, and hospitalization for other cardiac reasons or cardiac
intervention. Associations between patient characteristics and cardiac
outcomes were checked in a 3-level model (patient–center–country).
RESULTS: Most patients came from emerging countries (75%). Mitral
stenosis (MS) with or without mitral regurgitation (MR) was present in
273 women, isolated MR in 117. The degree of MS was mild in 20.9%,
moderate in 39.2%, severe in 19.8%, and severity not classified in the
remainder. Maternal death during pregnancy occurred in 1 patient with
severe MS. Hospital admission occurred in 23.1% of the women with MS,
and the main reason was heart failure (mild MS 15.8%, moderate 23.4%,
severe 48.1%; P1 was an
independent predictor of maternal cardiac events. Follow-up at 6 months
postpartum was available for 53%, and 3 more patients died (1 with
severe MS, 1 with moderate MS, 1 with moderate to severe MR).
mortality. We studied pregnancy outcomes in women with rheumatic
mitral valve disease.
METHODS: The Registry of Pregnancy and Cardiac Disease is an
international prospective registry, and consecutive pregnant women with
cardiac disease were included. Pregnancy outcomes in all women with
rheumatic mitral valve disease and no prepregnancy valve replacement
is described in the present study (n=390). A maternal cardiac event was
defined as cardiac death, arrhythmia requiring treatment, heart failure,
thromboembolic event, aortic dissection, endocarditis, acute coronary
syndrome, and hospitalization for other cardiac reasons or cardiac
intervention. Associations between patient characteristics and cardiac
outcomes were checked in a 3-level model (patient–center–country).
RESULTS: Most patients came from emerging countries (75%). Mitral
stenosis (MS) with or without mitral regurgitation (MR) was present in
273 women, isolated MR in 117. The degree of MS was mild in 20.9%,
moderate in 39.2%, severe in 19.8%, and severity not classified in the
remainder. Maternal death during pregnancy occurred in 1 patient with
severe MS. Hospital admission occurred in 23.1% of the women with MS,
and the main reason was heart failure (mild MS 15.8%, moderate 23.4%,
severe 48.1%; P1 was an
independent predictor of maternal cardiac events. Follow-up at 6 months
postpartum was available for 53%, and 3 more patients died (1 with
severe MS, 1 with moderate MS, 1 with moderate to severe MR).